At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Air Date: November 23, 2022 |
Length: 41:54 |
Download the transcript
Share this episode:
Parkinson's disease affects over 100,000 Canadians, and that number is growing each year. The economic burden is estimated to be $1.2 billion in direct and indirect costs associated with the neurodegenerative disease–for which we have no cure.
Could worms be the answer to developing potential therapies?
Caenorhabditis elegans is a small round worm that has been used to model Parkinson's disease. These worms share 40% of their genes with humans and have dopamine-producing neurons, the neurotransmitter that's dysregulated in the disease.
Dr. Lorraine Kalia's research looks at testing different compounds in
C. Elegans and how it can lead to a better understanding of Parkinson's disease and new therapeutic targets. The best part: some of these compounds are already approved for use in humans. Through Dr. Kalia's research we may be able to repurpose these compounds for the neurodegenerative condition.
Lorraine Kalia, MD, PhD, FRCPC is an Associate Professor in the Division of Neurology, Department of Medicine, University of Toronto and a Senior Scientist at the Krembil Brain Institute, University Health Network. She also holds appointments with the Tanz Centre for Research in Neurodegenerative Diseases and Department of Laboratory Medicine and Pathobiology, University of Toronto.
As a neurologist, she specializes in Parkinson's disease and related movement disorders at the Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program at Toronto Western Hospital, University Health Network.
Combined with her clinical expertise, she and her research team are focused on the critical molecular mechanisms responsible for neurodegeneration in Parkinson's disease and identifying therapeutic agents that can modulate or target these molecular mediators of neurodegeneration.